Publications by authors named "Julia Greene"

Claim this Profile
A
An Increasing Role for Cytoreductive Surgery in Metastatic Colorectal Cancer-National Trends in the Era of More Effective Systemic Therapy.
Stephanie Young, Julia Greene, Daniel Milgrom, Jessica Weiss, Melanie Goldfarb

J Surg Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promiscuous and regiospecific Vinca minor hydroxylases for opioid akuammine biosynthesis and monoterpenoid indole alkaloid diversification.
Zhan Mai, Matthew Bailey Richardson, Scott Galeung Alexander Mann, Julia Greene, Allyson Audrey Paul

Plant Physiol Biochem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Tommy A Brown, Elizabeth A Mittendorf, Diane F Hale, John W Myers, Kaitlin M Peace, Julia M Greene

Breast Cancer Res Treat· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Tommy A Brown, Kevin Byrd, Timothy J Vreeland, Guy T Clifton, Doreen O Jackson, Julia M Greene

Cancer Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Timothy J Vreeland, Jennifer K Litton, Na Qiao, Anne V Philips, Gheath Alatrash, Julia M Greene

Clin Immunol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
Garth S Herbert, Timothy J Vreeland, Guy T Clifton, Julia M Greene, Doreen O Jackson

Vaccine· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.
Mark O Hardin, Timothy J Vreeland, Guy T Clifton, Diane F Hale, Garth S Herbert, Julia M Greene

Immunotherapy· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Doreen O Jackson, Kevin Byrd, Timothy J Vreeland, Diane F Hale, Garth S Herbert, Julia M Greene

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Julia M Greene, Erika J Schneble, Doreen O Jackson, Diane F Hale, Timothy J Vreeland

Cancer Immunol Immunother· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragmentation injury to the innominate artery in a three-year-old child.
Julia M Greene, Jeremy W Cannon, W Darrin Clouse, Jerry W Pratt

Ann Thorac Surg· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis